Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
COMPUGEN LTD (CGEN) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/07/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "Notice of 2023 annual general meeting of shareholders of Compugen Ltd., proxy statement and proxy card",
"Notice of 2023 annual general meeting of shareholders of Compugen Ltd., proxy statement and proxy card"
08/07/2023 6-K Quarterly results
Docs: "6-K",
"Compugen Reports Second Quarter 2023 Results",
"F-2 - F-3 Condensed Consolidated Statements of Comprehensive Loss F-4 Condensed Consolidated Statements of Changes in Shareholders' Equity F-5 Condensed Consolidated Statements of Cash Flows F-6 Notes to Condensed Consolidated Financial Statements F-7 - F-15",
"MANAGEMENT'S DISCUSSION AND ANALYSIS OF RESULTS OF OPERATIONS AND FINANCIAL CONDITION"
06/13/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Compugen Regains Compliance with Nasdaq Minimum Bid Price Requirement"
05/15/2023 6-K Quarterly results
Docs: "6-K",
"Compugen Reports First Quarter 2023 Results"
05/03/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K"
03/10/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K"
03/06/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "Compugen Doses First Patient in Triple Combination COM701, COM902 and Pembrolizumab MSS CRC Proof of Concept Study",
"Compugen Doses First Patient in Triple Combination COM701, COM902 and Pembrolizumab MSS CRC Proof of Concept Study"
02/27/2023 6-K Quarterly results
Docs: "6-K",
"Compugen Reports Fourth Quarter and Full Year 2022 Results"
02/14/2023 6-K Quarterly results
01/31/2023 6-K Quarterly results
12/06/2022 6-K Quarterly results
12/02/2022 6-K Quarterly results
12/01/2022 6-K Quarterly results
11/16/2022 6-K Quarterly results
11/14/2022 6-K Quarterly results
11/07/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Compugen’s COM701 (anti-PVRIG) in Combination with Nivolumab Demonstrates Preliminary Anti-Tumor Activity and Potent Immune Activation in Metastatic MSS-CRC Patients",
"Compugen’s COM701 (anti-PVRIG) Induces Potent Immune Activation in MSS-CRC Patients"
11/02/2022 6-K Quarterly results
09/22/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Compugen Letter to Shareholders"
09/15/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K"
09/12/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Compugen Announces Appointment of Alberto Sessa as Chief Financial Officer"
08/04/2022 6-K Quarterly results
08/04/2022 6-K Quarterly results
08/04/2022 6-K Quarterly results
08/04/2022 6-K Quarterly results
05/16/2022 6-K Quarterly results
05/10/2022 6-K Quarterly results
02/24/2022 6-K Quarterly results
11/12/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"ARTICLE I.",
"Amendment No. 3 to Master Clinical Trial Collaboration Agreement, by and between Compugen Ltd. and Bristol-Myers Squibb Company",
"Squibb alongside $20 Million Equity Investment"
11/12/2021 6-K Quarterly results
Docs: "6-K",
"Escalation Study of COM701 with Opdivo ® and BMS-986207 at SITC 2021",
"Differentiation of PVRIG Compared to TIGIT and PD-1 as a Novel Checkpoint on the DNAM Axis at SITC 2021",
"Escalation Monotherapy Study of COM902 a High Affinity Anti-TIGIT Antibody at SITC 2021",
"Compugen Reports Third Quarter 2021 Results"
09/02/2021 6-K Quarterly results
07/29/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "Notice of 2021 Annual General Meeting of Shareholders of Compugen Ltd., Proxy Statement and Proxy Card",
"Notice of 2021 Annual General Meeting of Shareholders of Compugen Ltd., Proxy Statement and Proxy Card"
07/28/2021 6-K Quarterly results
Docs: "6-K",
"Compugen Reports Second Quarter 2021 Results",
"- - - - - - - - - - - - -",
"Public Offering"
06/08/2021 6-K Quarterly results
05/13/2021 6-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy